Janus Kinase (JAK) Inhibitors Market Report 2024 : Strategies And Recent Developments | Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi SA

"The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Janus Kinase JAK Inhibitors Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The janus kinase (jak) inhibitors market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $20.41 billion in 2024 at a compound annual growth rate (CAGR) of 18.1%. The growth in the historic period can be attributed to recognition of the role of jak-stat signaling pathway in diseases, increased prevalence of autoimmune disorders, unmet medical needs in rheumatology and dermatology, development of targeted therapies for inflammatory conditions, improvement in diagnostic capabilities for autoimmune diseases.

The janus kinase (jak) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $39.92 billion in 2028 at a compound annual growth rate (CAGR) of 18.3%. The growth in the forecast period can be attributed to growth of biopharmaceutical research and development, regulatory approvals for jak inhibitors in specific indications, expansion of clinical trials for jak inhibitor drugs, advances in personalized and precision medicine, adoption of jak inhibitors in combination therapies, integration of digital health technologies in autoimmune care. Major trends in the forecast period include focus on developing novel selective jak inhibitors for improved safety profiles, development of jak inhibitors with extended-release formulations, integration of artificial intelligence in jak inhibitor drug discovery, exploration of jak inhibitors in novel drug delivery systems, collaboration between pharmaceutical companies and research institutions.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12524&type=smp

Market Segmentation:
The janus kinase (jak) inhibitors market covered in this report is segmented -

1) By Inhibitors Type: Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib, Other Inhibitor Types
2) By Mode Of Administration: Injectable, Oral, Other Modes Of Administration
3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies
4) By Application: Autoimmune Disorders, Oncology, Inflammatory Disorders, Metabolic Disorders

Major Driver - Surging Instances Of Autoimmune Diseases Propel The Janus Kinase (JAK) Inhibitors Market
The increase in instances of autoimmune diseases is expected to propel the growth of the Janus kinase (JAK) inhibitors market. Autoimmune diseases are a broad group of disorders characterized by an abnormal immune response in which the immune system mistakenly attacks and damages healthy cells, tissues, and organs. Janus Kinase (JAK) inhibitors provide therapeutic benefits for autoimmune diseases by modulating the immune system, reducing inflammation, and alleviating symptoms such as rheumatoid arthritis. For instance, in December 2022, according to the National Psoriasis Foundation, a US-based non-profit organization serving people with Psoriasis and psoriatic arthritis, Psoriasis affected more than 8 million people in America and 125 million individuals worldwide, or 2 to 3% of the population. Furthermore, in September 2022, according to the Centers for Disease Control and Prevention, a US-based national public health agency, Diabetes was diagnosed in 28.7 million people of all ages, or 8.7% of the US population, and 5.7% of all US individuals with confirmed Diabetes-or 1.6 million people aged 20 and older-reported having type 1 diabetes and requiring insulin. Therefore, the increase in instances of autoimmune diseases is driving the growth of the Janus kinase (JAK) inhibitors market.

Competitive Landscape:
Major companies operating in the janus kinase (jak) inhibitors market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., GSK Plc., Takeda Pharmaceutical Company Ltd., Eli Lilly and Co., Gilead Sciences Inc., Boehringer Ingelheim Group, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation, Incyte Corporation, Kyowa Hakko Kirin Co. Ltd., Galapagos NV, Sierra Oncology Inc., Dizal Pharmaceutical, Reistone Biopharma Co. Ltd., CTI BioPharma Corp., Celon Pharma SA, Theravance Biopharma Inc., Aclaris Therapeutics Inc., Alexion Pharmaceuticals Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

Top Trend - Technological Breakthroughs Drive Product Innovation In The Janus Kinase (JAK) Inhibitors Market
Product innovation is a key trend gaining popularity in the Janus kinase (JAK) inhibitors market. Major companies operating in the Janus kinase (JAK) inhibitors market are focused on innovating technologically advanced solutions to sustain their position in the market. For instance, in May 2022, Eli Lilly and Company, a US-based pharmaceutical company, and Incyte, a Switzerland-based biopharmaceutical company, announced the approval of OLUMIANT (baricitinib) by the U.S. Food and Drug Administration (FDA). It is the first and only JAK inhibitor FDA-approved for treating COVID-19 in some hospitalized individuals who need varying levels of oxygen assistance. OLUMIANT is approved for treating adult hospital patients with extracorporeal membrane oxygenation (ECMO), non-invasive or invasive mechanical breathing, or COVID-19 disease 2019 (COVID-19).

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Janus Kinase JAK Inhibitors Market Characteristics
3. Janus Kinase JAK Inhibitors Market Trends And Strategies
4. Janus Kinase JAK Inhibitors Market - Macro Economic Scenario
5. Janus Kinase JAK Inhibitors Market Size And Growth
…..
27. Janus Kinase JAK Inhibitors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.